INDEX / DIRECTORY / CHEMIST WAREHOUSE

Chemist Warehouse

Pharmacies & Optics 87 CITED SOURCES UPDATED 2026-10-23 METHOD V6.5
Complicity Index score 208 /1000 D Tier D - Moderate
Military ↗ 0.00 Digital ↗ 0.00 Economic ↗ 2.50 Political ↗ 0.00
OWNERSHIP TREE 41 brands and group businesses View all

OpenIntel is reader-funded - no sponsors, no institutional money. Support OpenIntel →

Key Findings

  • Economic: Chemist Warehouse pursued Israeli market entry in 2022–2023, including a reported preparatory company managed by Uri Aldubi. No operating Israeli retail network was established by the audits; the vehicle’s legal identity, ownership and subsequent status remain unresolved.1, 2, 3, 4
  • Economic: Australian records establish Teva-branded pharmaceutical distribution, but the identified Chemist Warehouse product listing could not be independently verified live. Direct procurement from Teva and the manufacturing origin of Chemist Warehouse’s Australian inventory remain unverified.5, 6, 7, 8
  • Political: Jack Gance addressed Israel’s Knesset Health Committee on 21 March 2023 about import requirements and proposed market entry. The documented advocacy concerned commercial regulation, competition and consumer prices.9
  • Not found: No public evidence identified of Chemist Warehouse supplying Israeli military organisations, providing technology to Israeli security institutions, or operating in settlements. The documented New Zealand facial-recognition trial does not establish an Israeli surveillance nexus.10, 11, 12

Target Profile

FieldDetail
Company NameChemist Warehouse / CW Group Holdings Limited; parent: Sigma Healthcare Limited.13
JurisdictionAustralia. CW Group Holdings Limited is identified as the Australian corporate entity in the merger proceedings; state of incorporation: No public evidence identified.14
HeadquartersCorporate contact operations documented in Victoria, Australia; a more specific headquarters location is not established in the supplied audits.15
SectorPharmacy retailing and franchising, pharmaceutical wholesaling, healthcare retail support and distribution.10
OwnershipCW Group Holdings became wholly owned by listed Sigma Healthcare Limited, ASX: SIG, on 12 February 2025. Merger arrangements allocated approximately 85.75% of the combined group to former Chemist Warehouse shareholders collectively; this is not an individual founder’s holding.13, 14, 16
Key Executives / GovernanceMichael Sammells, chairman; Vikesh Ramsunder, managing director and CEO; Mario Verrocchi, Chemist Warehouse Group CEO and executive director; Jack Gance, non-executive director; Damien Gance and Danielle Di Pilla, directors. Jack and Sam Gance are documented founding principals.16, 17
Israeli-Nexus SummaryProposed Israeli expansion and commercial-regulatory engagement in 2022–2023; unresolved preparatory-vehicle status and qualified Teva-related retail evidence, without a verified Israeli operating network.1, 2, 3, 5, 6, 9

Executive Summary

Chemist Warehouse is an Australian pharmacy retail and franchising business within the Sigma Healthcare group. Sigma acquired CW Group Holdings on 12 February 2025, combining Chemist Warehouse’s retail network with pharmaceutical wholesale and distribution operations. Its documented Israel-related activity centres on proposed market entry, regulatory engagement and limited pharmaceutical supply-chain evidence.10, 13

The strongest direct nexus is the 2022–2023 expansion initiative. Israeli reporting documented discussions between Jack Gance and economic officials, an initial proposal for one or two stores, and later ambitions for a larger network. An August 2023 report stated that a company managed by Uri Aldubi had been established to advance the project. Its registered name, jurisdiction, shareholders, capital commitments and contractual relationships were not established. Subsequent operating disclosures did not identify an Israeli retail network, but they also did not resolve whether that preparatory vehicle continued, ceased activity or retained obligations.1, 2, 3, 4, 18

The pharmaceutical evidence requires similar qualification. Teva’s disclosures establish an Australian distribution channel involving an Israel-incorporated ultimate parent, and Australian product and government records confirm Rivaroxaban-Teva’s commercial availability. The audit identified a Chemist Warehouse listing consistent with a retail relationship, but could not independently verify its live contents. A Singapore registration documents Israeli manufacture for a corresponding product in that market; it does not establish the origin of Australian retail stock.5, 6, 7, 8

The political record establishes commercial advocacy, particularly Gance’s March 2023 parliamentary participation. It does not establish advocacy against Palestinian rights, support for Israeli military operations, or settlement financing. No public evidence identified of military supply contracts, Israeli security-technology provision or settlement operations. These limitations are substantive findings, not omissions to be filled through inference.9, 10, 11, 12

The fixed, human-vetted V6.5 result is BRS 208 - Tier D (Moderate Complicity). Economic activity supplies the sole nonzero V-domain result. The tier is a classification within the supplied scoring framework; it does not establish military involvement, settlement activity or a judicial finding of liability.

Timeline of Relevant Events

DateEvent
1972; 1997; 2000Jack and Sam Gance began operating pharmacies in Melbourne in 1972; My Chemist was established in 1997; the first Chemist Warehouse store opened in 2000.17
22 November 2018[pre-2020] Jack Gance addressed a Young Australia-Israel Chamber of Commerce masterclass and selected Save a Child’s Heart for the organiser’s allocation of 50% of ticket proceeds. The event’s donation amount and any continuing relationship are unknown.19
August 2022Israeli reporting documented proposed market entry and engagement with economic officials. The initial proposal involved one or two stores; Good Pharm discussions were described as preliminary.1, 18, 20
21 March 2023Gance participated remotely in the Knesset Health Committee’s proceedings on cosmetics and pharmacy regulation, discussing barriers to the proposed expansion.9
3 August 2023Ynet reported an Aldubi-managed preparatory company, regulatory engagement and prospective targets of approximately 30 outlets and NIS 1.5 billion annual revenue within five years. These were ambitions, not realised operations or revenue.2
13 May 2024An independent investment analysis considered Israeli entry unlikely without favourable regulatory changes. It did not establish dissolution or abandonment of the preparatory vehicle.4
7 November 2024The ACCC announced it would not oppose the Sigma–Chemist Warehouse merger, subject to court-enforceable undertakings addressing Australian competition concerns.14
12–13 February 2025Sigma implemented its acquisition of CW Group Holdings on 12 February and announced completion of the merger on 13 February.13, 21
July 2025; July 2026Reporting identified Chemist Warehouse as an investor in two Augmodo financing rounds. Its individual investment amounts and ownership percentages were not disclosed; the audits establish no Israeli nexus for those investments.22, 23
5 May; 26 August 2026Sigma’s expansion and results disclosures did not identify an operating Israeli retail network or separately reported Israeli revenue.3, 24
21 August; 12 October 2026Live testing of Auror Subject Recognition began at one Auckland store, followed by an official five-store trial. The disclosed underlying technology was Paravision, with biometric hosting in Australia.12
23 October 2026Research cutoff. The preparatory vehicle’s identity and subsequent legal status, Australian Teva inventory provenance, and implementation of Israeli market entry remained unresolved.2, 3, 5, 6, 7, 8, 4

Corporate Overview

Chemist Warehouse developed from the Gance family’s Australian pharmacy businesses, with Mario Verrocchi subsequently joining. The 2024 ACCC record described a franchisor, wholesaler and distributor supplying Chemist Warehouse, MyChemist, Ultra Beauty, My Beauty Spot and Optometrist Warehouse. Following the merger, the combined group also encompassed Sigma’s wholesale operations and pharmacy brands including Amcal, Discount Drug Stores, Guardian and PharmaSave.10, 14, 17

The acquisition establishes a formal parent–subsidiary relationship between Sigma and CW Group Holdings. Former Chemist Warehouse shareholders received the controlling collective interest under the transaction arrangements. Neither that collective holding nor the founders’ identities establishes Israeli beneficial control. No public evidence identified of Israeli state ownership, a golden share or Israeli state governance rights.13, 14, 16

The Israeli preparatory structure remains less defined. Ynet’s August 2023 account reported a company managed by Uri Aldubi, but supplied no registered name, company number, incorporation jurisdiction or ownership record. It therefore supports reported organisational preparation, without establishing a verified Israeli subsidiary or a particular legal relationship to CW Group Holdings. Aldubi’s separately identifiable business affiliations cannot be substituted for the unnamed vehicle.2

Likewise, preliminary discussions with Good Pharm and proposed participation by existing pharmacy operators do not establish executed franchise, distribution or partnership agreements. The audits found no verified Israeli stores, workforce, premises, retail sales or tax payments attributable to the project.2, 3, 18, 20, 24

Domain Summaries

Military: Military

Mechanism of Involvement

No public evidence identified of a contract, procurement award or supply agreement connecting Chemist Warehouse or Sigma to the Israeli Ministry of Defence, IDF, Israel Prison Service or Israel Border Police. The reviewed disclosures describe civilian pharmaceutical retailing, wholesaling and distribution.10, 13, 21

The military audit also identified no substantiated weapons manufacture, military-specific pharmaceutical line, defence-prime integration, military freight service or base-support arrangement. No public evidence identified of equipment or services supplied for settlement construction, checkpoints, detention facilities or Israeli military installations.10, 11

Counter-Arguments and Evidence Limits

The company’s strongest defence is the absence of an identified military relationship and the civilian character of its disclosed activities. Pharmaceutical distribution is not evidence of military supply merely because medicines can have military end users.10, 11

Official IDF information establishes that military prescription arrangements can involve specified civilian pharmacies. It does not identify Chemist Warehouse as a participant, supplier or contractual beneficiary. That general mechanism cannot support attribution to this company.11

The reviewed material also did not establish military-specific donations or defence-company roles for the identified principals. These are bounded negative findings: they record what the audit established, rather than proving that every possible private relationship has been disclosed.16

Named Entities and Evidence Map

Digital: Digital

Mechanism of Involvement

Chemist Warehouse has documented enterprise technology relationships, but the audit establishes no corresponding Israeli digital nexus. Microsoft’s August 2025 account describes an internal HR advisory assistant developed with Insurgence AI using Azure AI Foundry and Power Platform. Its disclosed purpose is employment-policy retrieval and draft responses subject to human review.26

Pharmx’s February 2026 announcement documents a multi-year electronic-data-interchange alliance covering Sigma wholesale operations and Chemist Warehouse’s Australian and New Zealand retail network. The disclosed engagement concerns pharmacy supply chains and related digital services, without an identified Israeli defence or intelligence customer.27

The New Zealand facial-recognition trial is a confirmed surveillance deployment. Chemist Warehouse identifies Auror, a New Zealand company, as supplier, Paravision as the underlying technology and Australian Microsoft Azure infrastructure as host. No public evidence identified connecting that trial to an Israeli surveillance supplier, Israeli processing infrastructure or Israeli state institution.12

Counter-Arguments and Evidence Limits

The company’s strongest defence is that the identified systems serve civilian retail, HR and supply-chain functions. Use of Microsoft or another multinational vendor does not establish participation in that vendor’s separate Israeli government or military engagements. No public evidence identified of Chemist Warehouse involvement in Project Nimbus or technology provision to Israeli security bodies.12, 26, 27

The facial-recognition notice describes restricted watchlists, deletion of nonmatching templates within seconds and review by at least two authorised staff before action. These are company disclosures about safeguards, not independent findings validating every aspect of the trial. They nevertheless delimit the documented purpose and prevent its recasting as an Israeli military-surveillance programme.12

Australian privacy disclosures name several possible overseas processing locations without specifically identifying Israel. Because those disclosures are not complete subprocessor inventories, they cannot prove that every downstream processing location has been excluded. No public evidence identified confirming processing within Israeli jurisdiction.28

Named Entities and Evidence Map

Economic: Economic

Mechanism of Involvement

The economic record establishes a sustained proposed-entry initiative during 2022–2023. Globes reported discussions between Gance and Ministry of Economy and Industry director-general Ron Malka; Ynetnews described an initial test of one or two stores. Subsequent reporting documented continued interest, regulatory obstacles and an Aldubi-managed company advancing the project.1, 2, 18

The August 2023 reporting described approaches to ministers, discussions with economic and competition authorities, and meetings with health funds. It also reported prospective ambitions of approximately 30 outlets and NIS 1.5 billion annual revenue within five years. Neither these discussions nor the targets establish binding agreements, expenditure commitments or realised Israeli income.2

A second, qualified connection concerns Teva. Its Australian modern-slavery statement identifies an Israel-incorporated ultimate parent and a distribution model principally using pharmaceutical wholesalers. Teva’s catalogue and Australian PBS documentation corroborate Rivaroxaban-Teva’s Australian commercial status. The identified Chemist Warehouse listing is consistent with retail availability, but its live contents and procurement route were not independently verified.5, 6, 7

The separate Singapore registration establishes Israeli manufacture for a Rivaroxaban-Teva 20mg product registered there. It does not establish that Australian-market tablets share that manufacturing origin. No public evidence identified establishing the production facility, batch provenance, importer of record or shipment route of the inventory offered through Chemist Warehouse Australia.5, 6, 7, 8

Counter-Arguments and Evidence Limits

The company’s strongest defence is that proposed expansion is not completed market entry. The audits identified no operating Israeli retail network, verified local workforce, executed pharmacy partnerships, binding distribution contracts or realised Israeli revenue. Sigma’s 2026 disclosures identify other international markets and UK expansion plans.2, 3, 24

The preparatory vehicle cannot be treated as a confirmed current Israeli subsidiary. Its incorporation jurisdiction and beneficial ownership remain unverified. Conversely, the absence of Israel from subsequent operating disclosures does not establish dissolution, formal withdrawal or the extinguishment of residual obligations. Continuity and cessation both remain unresolved.2, 3, 4

No public evidence identified of settlement-origin goods, settlement stores or deliveries, Israeli sovereign-debt holdings, military financing or profit remittances to an Israeli parent or state entity in the reviewed economic record.10, 16, 24

Chemist Warehouse’s investments in Augmodo are documented, but neither the US$37.5 million nor US$21 million round total represents its individual contribution. The audits establish no Israeli nexus for Augmodo; these investments therefore cannot be recast as Israeli technology financing.22, 23

Named Entities and Evidence Map

Political: Political

Mechanism of Involvement

The strongest documented political activity is Gance’s participation in the Knesset Health Committee on 21 March 2023. He discussed proposed entry, objections to import documentation and the affordability of products for Israeli consumers. The record establishes direct regulatory advocacy before Israeli parliamentary and government representatives.9

Earlier reporting independently documented Ministry of Economy engagement encouraging international retail competition. These interactions concern commercial policy; they do not establish support for military operations, settlement expansion or restrictions on Palestinian rights.1, 18

A separate historical institutional connection is the [pre-2020] November 2018 Young Australia-Israel Chamber masterclass. Gance selected Save a Child’s Heart, an Israel-based humanitarian medical charity, for the organiser’s allocation of 50% of ticket proceeds. The event record does not quantify the resulting donation or identify Chemist Warehouse as the transferring organisation.19

Counter-Arguments and Evidence Limits

The company’s strongest defence is the commercial substance of the advocacy and the humanitarian character of the documented charitable beneficiary. The parliamentary material concerns import requirements, competition and pricing. The Chamber event does not establish military fundraising, settlement financing or a continuing corporate sponsorship.9, 19

Gance’s references to his Jewish identity in the hearing do not establish additional corporate conduct. The evidentiary finding is his documented participation and statements about the proposed business initiative.9

No public evidence identified of an official corporate position supporting Israeli military operations, anti-Palestinian lobbying, anti-BDS funding, military-welfare donations or settlement contributions. No public evidence identified establishing continuation of the 2022–2023 Israel-specific advocacy after 19 July 2024.9, 16, 21, 29, 30

The audits also identified no settlement operating presence, Palestine-related employee sanctions or substantiated company-specific Israel-related technology campaign. These findings do not support expanding commercial engagement into a broader geopolitical allegation.10, 16, 26, 27, 29

Named Entities and Evidence Map

Complicity Index Score

Method: V6.5 - final, human-vetted values.

DomainIMPV-Domain Score
Military0.000.000.000.00
Digital0.000.000.000.00
Economic2.507.008.502.50
Political2.000.000.000.00

Economic supplies V_MAX 2.50, with the audited record centred on proposed investment, reported preparatory organisation and qualified pharmaceutical retail evidence; the fixed M and P values do not independently establish completed operations, investment amounts or procurement terms. The documented commercial advocacy accompanies Political I=2.00, while its fixed M=0.00 and P=0.00 leave that domain at zero; the supplied result is 208, Tier D. This is a scale-free, evidence-only, human-vetted assessment: all values are reproduced unchanged, with the audits’ unresolved findings retained.

Methodology Note

Footnotes

  1. Globes, “Australia’s Chemist Warehouse targets Israel’s market,” 15 August 2022. https://en.globes.co.il/en/article-australias-chemist-warehouse-targets-israels-pharmacy-market-1001421468 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  2. Ynet, report concerning Chemist Warehouse’s proposed Israeli entry, 3 August 2023. https://www.ynet.co.il/economy/article/skx2dvuj3 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14

  3. Sigma Healthcare, “Expansion plans revealed at key conference,” 5 May 2026. https://sigmahealthcare.com.au/expansion-plans-revealed-at-key-conference/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  4. Alex Sweet, Sweet Stocks, “Chemist Warehouse & Sigma Healthcare – a very special situation,” 13 May 2024. https://sweetstocks.substack.com/p/chemist-warehouse-and-sigma-healthcare ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  5. Teva Pharmaceuticals Australia Pty Ltd, “2022 Modern Slavery Statement.” https://modernslaveryregister.gov.au/statements/UucGLwMehdBXHiz/pdf/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  6. Teva Pharma Australia, “Rivaroxaban-Teva,” updated 22 April 2026. https://www.tevapharma.com.au/our-products/product-catalog/product-page-template/rivaroxaban ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  7. Australian Government, “2025 October PD Cycle - Confirmed Prices Report Excluding EFC,” October 2025. https://www.pbs.gov.au/industry/pricing/price-disclosure-spd/current-price-disclosure-files/2025-October-Cycle-Confirmed-Prices-Report-Excluding-EFC.PDF ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  8. Singapore National Drug Formulary, “RIVAROXABAN-TEVA FC TABLET 20MG [SIN17448P],” updated 16 September 2026. https://www.ndf.gov.sg/about-drugs/product-information/sin17448p/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  9. Open Knesset, Knesset Health Committee, Protocol No. 24, 21 March 2023. https://oknesset.org/meetings/2/2/2203269.html ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10

  10. Sigma Healthcare, “About Us.” https://sigmahealthcare.com.au/about-us/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13

  11. Israel Defense Forces, official military-pharmacy information. https://m.www.idf.il/%D7%94%D7%A9%D7%99%D7%A8%D7%95%D7%AA-%D7%A9%D7%9C%D7%99/%D7%AA%D7%A0%D7%90%D7%99-%D7%94%D7%A9%D7%99%D7%A8%D7%95%D7%AA-%D7%91%D7%A6%D7%94-%D7%9C/%D7%A8%D7%A4%D7%95%D7%90%D7%94/%D7%91%D7%AA%D7%99-%D7%9E%D7%A8%D7%A7%D7%97%D7%AA-%D7%A8%D7%A4%D7%95%D7%90%D7%99%D7%99%D7%9D/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  12. Chemist Warehouse New Zealand, “Auror Subject Recognition (ASR) Trial Notice,” 2026. https://www.chemistwarehouse.co.nz/aboutus/facial-recognition ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  13. Sigma Healthcare, “Merger with Chemist Warehouse - Implementation of Scheme,” 12 February 2025, reproduced by Market Index. https://www.marketindex.com.au/asx/sig/announcements/merger-with-chemist-warehouse-implementation-of-scheme-3A661470 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  14. ACCC, “Sigma and Chemist Warehouse proposed merger not opposed, subject to undertaking,” 7 November 2024, reproduced in Sigma’s ASX announcement. https://announcements.asx.com.au/asxpdf/20241107/pdf/06b472l7l2ns84.pdf ↩ ↩2 ↩3 ↩4 ↩5

  15. Sigma Healthcare, “Contact us.” https://sigmahealthcare.com.au/contact-us/ ↩

  16. Sigma Healthcare, “Annual Report 2025,” 17 September 2025. https://announcements.asx.com.au/asxpdf/20250917/pdf/06pb5y0rh9fgt4.pdf ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  17. Sigma Healthcare, “Our History.” https://sigmahealthcare.com.au/history/ ↩ ↩2 ↩3

  18. Ynetnews, “Australian drugstore Chemist Warehouse could enter Israeli market next year, chair says,” August 2022. https://www.ynetnews.com/business/article/rjwyj99a9 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  19. Young Australia-Israel Chamber of Commerce, past events archive, Jack Gance masterclass, 22 November 2018. https://www.yaicc.org.au/copy-of-events ↩ ↩2 ↩3 ↩4 ↩5

  20. Ynet, report on preliminary Chemist Warehouse and Good Pharm discussions, August 2022. https://www.ynet.co.il/economy/article/byzo86vrq ↩ ↩2 ↩3

  21. Sigma Healthcare, “Monumental day as Sigma Healthcare merges with Chemist Warehouse,” 13 February 2025. https://sigmahealthcare.com.au/sigma-healthcare-merges-with-chemist-warehouse/ ↩ ↩2 ↩3

  22. GeekWire, “Fresh off $37.5M round, Augmodo’s vision for spatial computing inside retail stores sharpens,” 31 July 2025. https://www.geekwire.com/2025/fresh-off-37-5m-round-augmodos-vision-for-spatial-computing-inside-retail-stores-sharpens/ ↩ ↩2 ↩3

  23. SiliconANGLE, “Spatial AI startup Augmodo raises $21M to expand beyond retail stores,” 13 July 2026. https://siliconangle.com/2026/07/13/spatial-ai-startup-augmodo-raises-21m-expand-beyond-retail-stores/ ↩ ↩2 ↩3

  24. Sigma Healthcare, “Annual results released for FY26,” 26 August 2026. https://sigmahealthcare.com.au/annual-results-released-for-for-fy26/ ↩ ↩2 ↩3 ↩4 ↩5

  25. AFSC Investigate, “Occupations,” company listings. https://investigate.afsc.org/occupations ↩

  26. Microsoft Source Asia, “A digital colleague: How Chemist Warehouse and Insurgence AI are rewriting the HR playbook,” 22 August 2025. https://news.microsoft.com/source/asia/features/a-digital-colleague-how-chemist-warehouse-and-insurgence-ai-are-rewriting-the-hr-playbook/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  27. Pharmx Technologies, “Pharmx and Sigma enter multi-year strategic alliance,” 23 February 2026. https://pharmx.com.au/wp-content/uploads/2026/02/3027717.pdf ↩ ↩2 ↩3 ↩4 ↩5

  28. Chemist Warehouse Australia, “Privacy Statement,” archived copy. https://web.archive.org/web/20260728071126/https://www.chemistwarehouse.com.au/help-centre/terms-and-policies/privacy-statement ↩

  29. Sigma Healthcare, “Sustainability.” https://sigmahealthcare.com.au/about-us/sustainability/ ↩ ↩2

  30. Australian Electoral Commission, Transparency Register. https://transparency.aec.gov.au/ ↩